Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 12/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17803022 | 1.00 | EPHX2 (0.39) | EPHX2GRM1ADORA3MAPK8MAPK10 | |
| SCHEMBL2078838 | 0.85 | — | — | |
| SCHEMBL9845543 | 0.82 | — | — | |
| SCHEMBL28034929 | 0.80 | CHRNB2 (0.38) | EPHX2GRM1ADORA3MAPK8MAPK10 | |
| SCHEMBL28003109 | 0.80 | CHRNB2 (0.38) | EPHX2GRM1ADORA3MAPK8MAPK10 | |
| SCHEMBL28034927 | 0.80 | CHRNB2 (0.38) | EPHX2GRM1ADORA3MAPK8MAPK10 | |
| SCHEMBL23156507 | 0.80 | EPHX2 (0.32) | EPHX2 | |
| SCHEMBL1060400 | 0.79 | CHRNB2 (0.36) | HSD17B10 | |
| SCHEMBL890380 | 0.79 | CHRNB2 (0.36) | HSD17B10 | |
| SCHEMBL4279 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-01-06 | — | — | US | disclosed |
| WO-2022006456-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-01-06 | — | — | WO | disclosed |
| CN-113666920-A | Preparation method of benzoxazole compound and application of benzoxazole compound in field of medicine | 上海华汇拓医药科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2020-03-24 | — | — | US | disclosed |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | MERCK SHARP & DOHME CORP. (US) | 2019-10-15 | — | — | US | disclosed |
| WO-2019193062-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE | ABBVIE S.Á.R.L (LU) | 2019-10-10 | — | — | WO | disclosed |
| EP-1397363-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | Bayer HealthCare AG (DE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1370531-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | Celltech R & D Limited (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| WO-2002098880-A1 | 5-ETHYL-IMIDAZOTRIAZINONES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-20020169336-A1 | Phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2002-11-14 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2002068393-A1 | PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS | CELLTECH R & D LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-4014922-A | CYCLOPROPYL SUBSTITUTED ESTERS; MITICIDES | ZOECON CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
| US-3948961-A | CYCLOPROPYL ALKYL CARBOXYLATES, MITICIDE, INSECTICIDE | ZOECON CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597378-B2 | Tetrahydroisoquinolines for use as MOR/NOP dual agonists | OPRL1, OPRM1, OPRK1 | EPHX2 1588/4885GRM1 31/4885ADORA3 231/4885 |
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | EPHX2 4392/4885GRM1 2431/4885ADORA3 2967/4885 |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | EPHX2 4392/4885GRM1 2431/4885ADORA3 2967/4885 |
| US-10442819-B2 | Tricyclic compounds as inhibitors of mutant IDH enzymes | IDH3A, IDH2, IDH3B | EPHX2 677/4885GRM1 3513/4885ADORA3 4392/4885 |
| US-10626081-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | EPHX2 592/4885GRM1 870/4885ADORA3 645/4885 |
| US-20020169336-A1 | Phenylalanine enamide derivatives | CCR1, AHR, PAH | EPHX2 760/4885GRM1 1204/4885ADORA3 1528/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | EPHX2 1899/4885GRM1 84/4885ADORA3 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.